921,587 Shares in InspireMD, Inc. $NSPR Purchased by Ghisallo Capital Management LLC

Ghisallo Capital Management LLC purchased a new position in InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 921,587 shares of the company’s stock, valued at approximately $2,221,000. Ghisallo Capital Management LLC owned approximately 2.18% of InspireMD at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Rosalind Advisors Inc. grew its stake in shares of InspireMD by 70.6% in the 3rd quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after purchasing an additional 1,616,644 shares during the last quarter. Ingalls & Snyder LLC acquired a new stake in InspireMD during the third quarter valued at approximately $542,000. Uniting Wealth Partners LLC acquired a new stake in InspireMD during the third quarter valued at approximately $51,000. Aberdeen Group plc bought a new stake in InspireMD during the third quarter worth approximately $5,979,000. Finally, Huntleigh Advisors Inc. boosted its holdings in InspireMD by 112.5% during the third quarter. Huntleigh Advisors Inc. now owns 264,004 shares of the company’s stock worth $636,000 after buying an additional 139,776 shares in the last quarter. Institutional investors own 44.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Loop Capital set a $5.00 price target on InspireMD in a report on Tuesday, February 24th. Maxim Group started coverage on InspireMD in a research note on Monday, February 2nd. They set a “buy” rating and a $6.00 price objective for the company. Finally, Lake Street Capital restated a “buy” rating on shares of InspireMD in a report on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, InspireMD currently has a consensus rating of “Buy” and a consensus target price of $5.00.

Insider Buying and Selling

In other InspireMD news, insider Shane Thomas Gleason sold 17,593 shares of the stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $1.62, for a total transaction of $28,500.66. Following the transaction, the insider directly owned 1,174,664 shares of the company’s stock, valued at $1,902,955.68. This represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 61,194 shares of company stock worth $99,188 over the last 90 days. Corporate insiders own 34.06% of the company’s stock.

InspireMD Price Performance

Shares of NYSE NSPR opened at $1.65 on Friday. InspireMD, Inc. has a one year low of $1.51 and a one year high of $2.99. The business’s 50-day moving average price is $1.70 and its two-hundred day moving average price is $2.01. The company has a market capitalization of $69.91 million, a P/E ratio of -2.20 and a beta of 0.87.

InspireMD Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.